News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

AF does not reduce dapagliflozin efficacy in HF patients
10 Nov 2022
byStephen Padilla
The presence of atrial fibrillation (AF) at baseline does not appear to modify the benefits of dapagliflozin, compared with placebo, on symptoms and clinical events in patients with heart failure and preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), according to a study.








